American Association for Cancer Research

Table 4.

Multivariable analysis of odds for PSMA-PET M1 disease (n = 200)

Variable	n (%)	OR	95% CI	P
Age ≥65 years	151 (76)	0.6	0.3–1.3	0.23
Gleason score of ≥8	151 (76)	1.1	0.5–2.3	0.80
PSA ≥5.5 ng/mL	97 (49)	2.0	1.1–3.6	0.03^a
PSADT of ≤6 months (n = 132^b)	85 (43)	1.6	0.8–3.3	0.22
Locoregional disease pN1	45 (23)	2.7	1.3–6.0	0.01^a
RPE and SRT	40 (20)	4.6	2.0–11.0	<0.01^a
PRT	64 (32)	3.1	1.5–6.1	0.02^a

Variable	n (%)	OR	95% CI	P
Age ≥65 years	151 (76)	0.6	0.3–1.3	0.23
Gleason score of ≥8	151 (76)	1.1	0.5–2.3	0.80
PSA ≥5.5 ng/mL	97 (49)	2.0	1.1–3.6	0.03^a
PSADT of ≤6 months (n = 132^b)	85 (43)	1.6	0.8–3.3	0.22
Locoregional disease pN1	45 (23)	2.7	1.3–6.0	0.01^a
RPE and SRT	40 (20)	4.6	2.0–11.0	<0.01^a
PRT	64 (32)	3.1	1.5–6.1	0.02^a

Abbreviations: PRT, primary radiotherapy; RPE, radical prostatectomy; SRT, salvage radiotherapy.

^aP < 0.05.

^bOn the basis of univariate analysis.